ClinicalTrials.gg
TerminatedNCT02905643Updated Feb 22, 2024

Discerning Pseudoprogression vs True Tumor Growth in GBMs

An observational study in Glioblastoma, sponsored by Ascension Health. Terminated. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Ascension Health · Observational

How we know

Why this study was terminated
Investigator left institution

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1
Ages
18 Years to 99 Years
Sex
All
01

Study summary

One-third of all primary brain tumors are astrocytomas, the most common type of glioma. Grade 4 astrocytomas, more commonly known as glioblastomas (GBMs), represent about 50% of all gliomas (annual incidence of over 3 per 100,000) and are associated with high mortality rates and median patient survival of just 12-15 months post-diagnosis. Treatment response is assessed by measuring post-treatment tumor size on contrast-enhanced magnetic resonance images (MRI). However, radiation and chemotherapy cause inflammatory and necrotic changes which, like actual tumor progression itself, demonstrate contrast enhancement on the first post-treatment MRI scan. This enhancement eventually subsides (typically within 6 months of treatment) and is known as pseudoprogression (PsP). Currently, there is no gold standard noninvasive tool for distinguishing between pseudoprogression and progressive disease. Dynamic susceptibility-weighted contrast-enhanced perfusion MRI (DSC perfusion MRI) permits measurement of hemodynamic imaging variables. Previous literature reports attempted to use some or all of these metrics to assess their utility in distinguishing PsP from true cancer progression. These studies showed mixed results, likely due to a number of factors, including poor statistical power, poorly defined PsP, analysis of multiple cancer grades and types, and varied analysis methodologies. The investigators aim to address these issues in this study.

Read the detailed description

See BRIEF SUMMARY section

02

Conditions studied

  • Glioblastoma

Keywords

  • Pseudoprogression
  • Brain Cancer
03

In context

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's enrollment of 1 is below the median of 60 across 208 observational studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Ascension Health is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals who have or might have a brain tumor which may be a glioblastoma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years of age or older.
  • Participants must be able to read and comprehend the English language.
  • In agreement with the care providing physician, participants must be willing to have surgery to remove possible brain tumor.
  • Participants must have a MRI scan within 24 hours after the tumor is removed (if a tumor is confirmed).
  • Participants must have the tumor analyzed by the laboratory and pathology departments and receive the diagnosis of glioblastoma.
  • Participants must be willing to follow the Stupp treatment protocol (this treatment plan and its' procedures are considered the standard for treating glioblastoma). (The Stupp protocol is the name of the radiation and chemotherapy plan that has been found to help in many cases of glioblastoma.)
  • Participants must be willing to follow any additional study procedures (including having all follow-up MRIs performed at St. Vincent 86th St).

Exclusion criteria

Exclusion Criteria:

  • Participants are less than 18 years of age.
  • Participants have had surgery for your brain tumor and NOT received the diagnosis of glioblastoma
  • Participants and care providing physician have decided NOT to follow the Stupp protocol (treatment plan) for glioblastoma treatment. (Deviations or interruptions are allowed if clinically indicated)
  • Participants are not having a MRI scan within 24 hours after brain tumor surgery.
  • Participants are not willing to follow the study procedures.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1 participant (actual)
Patient registry
No

Groups and cohorts

  • Study subjects

    Patients who have or might have a brain tumor which may be a glioblastoma.

    Other: Study subjects

Interventions

  • OtherStudy subjects

    This study does not include an intervention it is only observational.

06

What researchers measure

Primary outcomes

  1. Imaging parameter utility for pseudoprogression vs. true tumor growth

    The primary outcome of this study is to assess the utility of peak height, peak signal recovery, apparent diffusion coefficient, and cerebral blood volume (and their relative values) in determining, positive predictive values (PPV), negative predictive values (NPV), and likelihood ratios (LR) for identifying pseudo progression versus true tumor growth.

    Time frame: Up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Feb 2018, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2016
First posted
Sep 19, 2016
StartActual
Sep 2016
Primary completionActual
Feb 13, 2018
CompletionActual
Feb 13, 2018
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02905643
Lead sponsor
Ascension Health
Responsible party
Sponsor
First posted
Sep 19, 2016
Start date
Sep 2016
Primary completion
Feb 13, 2018
Completion
Feb 13, 2018
Last update
Feb 22, 2024

Study contacts

Eric Beltz, MD
principal investigator · Northwest Radiology Network, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion